MD-CARE Act Results: Exon Skipping from Lab to Patient

Originally signed into law in 2001, the MD-CARE Act has birthed key discoveries in the muscular dystrophies, including the scientific justification for why exon skipping therapies could potentially work in humans.

Without it being passed again in 2014, we risk a drastic reduction in potential scientific discoveries like we have seen over the past decade. Tell Congress to pass the MD-CARE Act this year and help us continue these advancements in research that are getting us closer to effective therapies and treatments for Duchenne. 

Click here to take action now!

Views: 222


You need to be a member of PPMD Community to add comments!

Join PPMD Community

Need help using this community site? Visit Ning's Help Page.



© 2021   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service